Grant Details
Title: Buprenorphine Effect on Suicidal Behavior
Funder: NIMH
Grant Number: U19MH121738-02S2 (supplement to main MHRN cooperative agreement)
Grant Period: 9/17/2020 – 8/31/2022
Narrative: This large observational study will evaluate the effects of initiating buprenorphine treatment on subsequent suicidal behavior among people with opioid use disorder, including those with and without co-occurring mental health conditions or other known risk factors for suicidal behavior. We will use comprehensive health records data from four large health systems serving a combined member/patient population of approximately 11 million. Analyses will examine the overall effect of buprenorphine treatment on subsequent suicide attempts or death, heterogeneity of effects in patient subgroups, and specificity of effects to buprenorphine vs other medications.
We will be using previously developed suicide risk prediction tools to compare the outcomes of individuals who do and do not use buprenorphine with similar baseline suicide risk.
- Lead Site: KPWA
- Overall PI: Greg Simon
- Participating Sites/Subcontractors:
- KPNC – Site PI: Cynthia Campbell
- KPSC – Site PI: Rulin Hechter
- Henry Ford – Site PI: Brian Ahmedani
- Funder Contacts:
- Science Officer: Susan Azrin
- Program Official: Michael Freed
- Grants Management Official: Julie Bergerud
- Awarded Budget (Total Cost):
- Year 1: $514,616
- Year 2: $274,321
Documents & Reports
Funding Announcement: PA-18-591
- Submitted Proposal
Personnel Contact List
Human Subjects: YES
- IRB Review:
- KPWA is single IRB reviewing for KPWA, KPNC, and KPSC – Approved waiver of consent for use of records data
- Henry Ford determined to be exempt
- KPWA IRBnet File: [1649129]
Clinical Trial: NO
Publications
Change Request Form
See something that needs to be changed? Complete the form below to submit your request.